Recent studies have shown that the quantification of PD‐L1 in cancer cells by QCS in patients with NSCLC not only surpasses the precision attained by trained diagnostic pathologists but also identifies a broader population of patients who may derive significant benefit from immunotherapy [7, 8]. The gene discussed is CD274; the disease is cancer.